Drug intelligence / Profile preview

Lactofiltrum

Development stage: Phase 3
Lead developer: Avva Pharmaceuticals
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactofiltrum is an oral combination product containing hydrolyzed lignin (a natural enterosorbent) and lactulose (a synthetic prebiotic disaccharide). Hydrolyzed lignin binds and removes toxins, pathogenic bacteria, heavy metals, allergens, medications, and metabolic byproducts from the gastrointestinal tract. Lactulose is not absorbed in the upper GI tract; it reaches the colon where it is fermented by beneficial gut bacteria (bifidobacteria and lactobacilli), promoting their growth. This dual action supports detoxification of the gut while restoring healthy intestinal microflora balance. Clinically tested primarily for management of atopic dermatitis/eczema via modulation of the gut-skin axis, as well as for intestinal dysbiosis (including after antibiotics), irritable bowel syndrome, hepatic conditions (hepatitis/cirrhosis), allergic diseases such as urticaria, and bacterial vaginosis[1][2][4][5][7][8].

Brand names: Lactofiltrum
Other names: lactulose/lignin hydrolytic

Beyond the preview

Go deeper on Lactofiltrum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactofiltrum.

Explore the full profile